Ignite Creation Date:
2025-12-24 @ 4:35 PM
Ignite Modification Date:
2025-12-29 @ 5:51 PM
Study NCT ID:
NCT01536366
Status:
COMPLETED
Last Update Posted:
2015-08-20
First Post:
2012-01-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
Sponsor:
Bial - Portela C S.A.
Organization:
Study Overview
Official Title:
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
Detailed Description:
Single-centre, open-label, randomised, two-way crossover study in healthy young male and female volunteers
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: